261 related articles for article (PubMed ID: 35039987)
1. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.
Rodrigues CL; de Freitas HC; Lima PRO; de Oliveira Junior PH; Fernandes JMA; D'Almeida JAC; Nóbrega PR
Neurol Sci; 2022 Apr; 43(4):2271-2276. PubMed ID: 35039987
[TBL] [Abstract][Full Text] [Related]
2. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka KV
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis and COVID-19: A case series and comparison with literature.
Saied Z; Rachdi A; Thamlaoui S; Nabli F; Jeridi C; Baffoun N; Kaddour C; Belal S; Ben Sassi S
Acta Neurol Scand; 2021 Sep; 144(3):334-340. PubMed ID: 33914898
[TBL] [Abstract][Full Text] [Related]
5. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
Tereshko Y; Gigli GL; Pez S; De Pellegrin A; Valente M
J Neurol; 2023 Feb; 270(2):601-609. PubMed ID: 36352330
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature.
Patelli G; Bencardino K; Tosi F; Pugliano M; Lanzani F; Innocenti A; Rinaldo A; Mauri G; Cerea G; Sartore-Bianchi A; Torre M; Agostoni EC; Siena S
J Med Case Rep; 2021 Feb; 15(1):32. PubMed ID: 33526108
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
[TBL] [Abstract][Full Text] [Related]
8. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C; Stascheit F; Eckert C; Pawlitzki M; Schroeter CB; Huntemann N; Mergenthaler P; Arat E; Öztürk M; Foell D; Schreiber S; Vielhaber S; Gassa A; Stetefeld H; Schroeter M; Berger B; Totzeck A; Hagenacker T; Meuth SG; Meisel A; Wiendl H; Ruck T
J Neuroinflammation; 2022 Apr; 19(1):89. PubMed ID: 35413850
[TBL] [Abstract][Full Text] [Related]
9. Plasma exchange for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay.
Galassi G; Marchioni A
Acta Neurol Belg; 2021 Jun; 121(3):633-642. PubMed ID: 33811309
[TBL] [Abstract][Full Text] [Related]
11. Does the virus or the doctor promote myasthenic crises in COVID-19 patients with myasthenia?
Finsterer J; Ghosh R
J Clin Anesth; 2021 Jun; 70():110166. PubMed ID: 33472763
[No Abstract] [Full Text] [Related]
12. Myasthenia Gravis Exacerbation Following Immunization With the BNT162b2 mRNA COVID-19 Vaccine: Report of a Case and Review of the Literature.
Papadopoulou M; Stefanou MI; Palaiodimou L; Tsivgoulis G
Neurohospitalist; 2023 Jul; 13(3):303-307. PubMed ID: 37435091
[TBL] [Abstract][Full Text] [Related]
13. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
; Jacob S; Muppidi S; Guidon A; Guptill J; Hehir M; Howard JF; Illa I; Mantegazza R; Murai H; Utsugisawa K; Vissing J; Wiendl H; Nowak RJ
J Neurol Sci; 2020 May; 412():116803. PubMed ID: 32247193
[No Abstract] [Full Text] [Related]
14. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
Gamez J; Gamez A; Carmona F
Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.
Furlan JC; Barth D; Barnett C; Bril V
Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889
[TBL] [Abstract][Full Text] [Related]
16. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Singh S; Govindarajan R
Clin Neurol Neurosurg; 2020 Sep; 196():106045. PubMed ID: 32634699
[TBL] [Abstract][Full Text] [Related]
18. Myasthenic crisis.
Chaudhuri A; Behan PO
QJM; 2009 Feb; 102(2):97-107. PubMed ID: 19060020
[TBL] [Abstract][Full Text] [Related]
19. Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection.
Hoang P; Hurtubise B; Muppidi S
Neurology; 2020 Nov; 95(18):840-843. PubMed ID: 32817186
[No Abstract] [Full Text] [Related]
20. COVID-19 infection in myasthenia gravis: Clinical course and outcomes.
Thomas EV; Bou G; Barton S; Hutto S; Garcia-Santibanez R
Muscle Nerve; 2023 Aug; 68(2):171-175. PubMed ID: 37326164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
